{"schema_version":"secwatch.filing_event.v1","accession":"0001453687-24-000100","form_type":"8-K","ticker":"RNAC","cik":"0001453687","company_name":"Cartesian Therapeutics, Inc.","filed_at":"2024-08-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:13.106202+00:00","generated_at":"2026-05-31T10:48:39.792204+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Cartesian reports positive Phase 2b MG data, Q2 net income $13.8M, $130M PIPE","bullets":["Phase 2b trial of Descartes-08 in MG met primary endpoint: 71% (10/14) of treated patients vs 25% (3/12) placebo had ≥5-point MGC improvement at Month 3 (p=0.018).","Q2 2024 net income of $13.8M ($0.58/share) vs net loss of $11.4M ($2.23/share) in Q2 2023; revenue included $30M milestone from Sobi.","Completed $130M PIPE financing in July 2024; cash and equivalents $88.9M at June 30, 2024, expected to fund Phase 3 MG trial and early commercial prep.","Dosed first SLE patient in Phase 2 trial; IND filing for pediatric basket study expected by year-end 2024; Descartes-15 Phase 1 expected H2 2024.","Appointed Dr. Kemal Malik to board; End-of-Phase 2 FDA meeting expected by year-end 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001453687-24-000100","json":"https://secwatch.observer/filing/0001453687-24-000100.json","markdown":"https://secwatch.observer/filing/0001453687-24-000100.md","text":"https://secwatch.observer/filing/0001453687-24-000100.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1453687/000145368724000100/0001453687-24-000100-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1453687/000145368724000100/rnac-20240808.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T10:48:39.792204+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}